HomeNDC LookupDrug shortages › Docetaxel Injection

Docetaxel Injection shortage

Docetaxel Injection is currently listed in shortage by the FDA. The FDA lists 2 affected products. This page was last refreshed from FDA data on Sep 19, 2026.

To Be Discontinued ⚠ Supply risk: High Oncology 2 products 211 days First posted Feb 20, 2026 Updated Feb 20, 2026
Here’s the bottom line

Ingenus Pharmaceuticals is permanently discontinuing its docetaxel injection 10 mg/1 mL. Other manufacturers — including Hikma, Hospira, Sanofi-Aventis, and Accord Healthcare — have not reported a shortage and still list docetaxel injection products.

Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).

Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →
2
Affected NDCs
1
Reporting manufacturers
0/1
Reporting mfrs supplying
0/1
Affected strengths supplied
211
Days in shortage
Source: FDA Drug Shortages Database API (openFDA). Last refreshed Sep 19, 2026 · yesterday

What’s in shortage — at a glance

These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Docetaxel Injection. Other makers that haven’t reported a problem are shown in the green card below.

Availability of affected NDCs
From the FDA shortage report
2 NDCs
To be discontinued 2
Affected strengths still supplied
Among manufacturers reporting this shortage
0/1 strengths
No supply 1
FDA-reporting manufacturers with supply
Among manufacturers reporting this shortage
0/1 makers
No supply 1
✓ Other manufacturers not reporting a shortage
Still-marketed Docetaxel Injection from companies that have not filed an FDA shortage — these are not counted in the figures above. Stock can still vary by pharmacy.
Hikma Pharmaceuticals USA Inc. Hospira, Inc. Sanofi-Aventis U.S. LLC Accord Healthcare Inc. Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. Sagent Pharmaceuticals
See all other options & details →
Shortage timeline
  1. Feb 20, 2026
    Currently in shortage
    2 of 2 products affected.
  2. Feb 20, 2026
    First reported to the FDA
    2 products first listed.

Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.

What exactly is on backorder — by manufacturer

Manufacturer: Ingenus Pharmaceuticals LLC 📞 866-321-5031 2 NDCS click to expand
Status NDC / product Strength Availability Related information Reason
To Be Discontinued Docetaxel, Injection, 10 mg/1 mL (NDC 50742-431-08) NDC 50742-0431-08 A business decision was made to discontinue manufacture of the drug.
To Be Discontinued Docetaxel, Injection, 10 mg/1 mL (NDC 50742-463-16) NDC 50742-0463-16 A business decision was made to discontinue manufacture of the drug.

These rows are manufacturer reports to the FDA for Docetaxel Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Docetaxel Injection? options further down this page.

Why is Docetaxel Injection in shortage?

Ingenus Pharmaceuticals has made a business decision to permanently stop making their version of Docetaxel Injection 10 mg/1 mL. This affects two specific package configurations they produced (NDC 50742-463-16 and NDC 50742-431-08). No specific reason beyond it being a business decision was shared publicly.

It's worth knowing that this report reflects only what Ingenus Pharmaceuticals filed with the FDA — it covers just their products, not every manufacturer of docetaxel out there.

Based on the manufacturer-reported reason(s) and notes on file with the FDA for Docetaxel Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.

What should I do if I take Docetaxel Injection?

Docetaxel Injection is currently on the FDA shortage list. I want to walk you through what this means so you can plan your next steps calmly.

The affected strength is the 10 mg/1 mL injection, and right now there is no available source reported for it. The manufacturer that filed this report, Ingenus Pharmaceuticals, states this is a business decision to discontinue making the drug. Because this product is listed "to be discontinued," this particular supply problem may be permanent. That said, this report reflects only one manufacturer — docetaxel is made by other companies too, so the medicine itself is still on the market in various forms and strengths.

Here is what I suggest:

  • Do not stop, skip, or change your treatment on your own — this medicine is part of a carefully planned regimen.
  • Since your exact strength is being discontinued, talk with your prescriber or pharmacist soon. They can look into the same medicine from another maker (for example, docetaxel is also produced by Hospira, Sagent, Hikma, Sanofi-Aventis, Accord, and Avet), though it may not sit in local stock and may come in a different concentration.
  • Your care team can choose the right option for your treatment plan.

Manufacturer contact numbers are listed on this page for reference; your pharmacy usually handles those calls. This is national, manufacturer-reported data and may not match your pharmacy's actual stock.

See “Where else can I get Docetaxel Injection?” below ↓ The same medicine from manufacturers not reporting a shortage, alternative dosage forms, and therapeutic equivalents with pricing.
If you are a patient:
  • Don’t stop or change the medication on your own — talk to your prescriber first.
  • If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
  • Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
  • Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Keep reading
Our full Docetaxel guide

Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.

Read the Docetaxel guide →

Where else can I get Docetaxel Injection?

FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Docetaxel Injection is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.

Same medicine, other manufacturers (not reported short)

Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:

ProductStrengthForm / routeManufacturerNDC
Docetaxel DOCETAXEL 20 mg/mL Injection, Solution, Concentrate · Intravenous Hikma Pharmaceuticals USA Inc. 00143-9204-01
Docetaxel DOCETAXEL ANHYDROUS 10 mg/mL Injection, Solution · Intravenous Hospira, Inc. 00409-0016-01
Docetaxel DOCETAXEL 20 mg/mL Injection, Solution · Intravenous Hospira, Inc. 00409-0365-01
Docetaxel DOCETAXEL 20 mg/mL Injection, Solution, Concentrate · Intravenous Sanofi-Aventis U.S. LLC 00955-1020-01
Docetaxel DOCETAXEL 80 mg/4mL Injection, Solution, Concentrate · Intravenous Sanofi-Aventis U.S. LLC 00955-1021-04
Docetaxel DOCETAXEL 160 mg/8mL Injection, Solution, Concentrate · Intravenous Sanofi-Aventis U.S. LLC 00955-1022-08
Docetaxel DOCETAXEL ANHYDROUS 20 mg/mL Injection, Solution, Concentrate · Intravenous Accord Healthcare Inc. 16729-0267-63
Docetaxel DOCETAXEL 20 mg/mL Injection · Intravenous Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. 23155-0903-31
Docetaxel DOCETAXEL 80 mg/4mL Injection · Intravenous Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. 23155-0904-31
Docetaxel DOCETAXEL 160 mg/8mL Injection · Intravenous Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. 23155-0905-31
Docetaxel DOCETAXEL ANHYDROUS 20 mg/mL Injection, Solution · Intravenous Sagent Pharmaceuticals 25021-0245-01
Docetaxel DOCETAXEL ANHYDROUS 10 mg/mL Injection · Intravenous Sagent Pharmaceuticals 25021-0254-08
Therapeutic equivalents & pricing 23 productsclick to expand

Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.

ProductManufacturerPackageNADAC $/unitAB ratingAvailability
Docetaxel 10 mg/mLNDC 00409-0016-01 Hospira, 1 vial AP FDA listed
Docetaxel 10 mg/mLNDC 00409-0201-02 Hospira, 1 vial AP FDA listed
Docetaxel 10 mg/mLNDC 00409-1732-01 Hospira, 1 vial AP FDA listed
Docetaxel 10 mg/mLNDC 00409-7870-01 Hospira, 1 vial AP FDA listed
Docetaxel 10 mg/mLNDC 25021-0254-08 Sagent 1 vial AP FDA listed
Docetaxel 10 mg/mLNDC 43066-0001-01 Baxter 1 vial AP FDA listed
Docetaxel 10 mg/mLNDC 43066-0006-01 Baxter 1 vial AP FDA listed
Docetaxel 10 mg/mLNDC 43066-0010-01 Baxter 1 vial AP FDA listed
Docetaxel 10 mg/mLNDC 43066-0046-08 Baxter 1 vial AP FDA listed
Docetaxel 10 mg/mLNDC 43066-0048-16 Baxter 1 vial AP FDA listed
Docetaxel 10 mg/mLNDC 46708-0678-02 Alembic 1 vial AP FDA listed
Docetaxel 10 mg/mLNDC 55150-0379-01 Eugia 1 vial FDA listed
Docetaxel 10 mg/mLNDC 55150-0380-01 Eugia 1 vial FDA listed
Docetaxel 10 mg/mLNDC 62332-0678-02 Alembic 1 vial AP FDA listed
Docetaxel 10 mg/mLNDC 66758-0050-01 Sandoz 1 vial AP FDA listed
Docetaxel 10 mg/mLNDC 67457-0532-08 Mylan 1 vial AP FDA listed
Docetaxel 10 mg/mLNDC 67457-0533-16 Mylan 1 vial AP FDA listed
Docetaxel 10 mg/mLNDC 68083-0400-01 Gland 1 vial AP FDA listed
Docetaxel 10 mg/mLNDC 68083-0401-01 Gland 1 vial AP FDA listed
Docetaxel anhydrous 10 mg/mLNDC 71288-0144-08 Meitheal 1 vial AP FDA listed
Docetaxel 10 mg/mLNDC 72078-0040-08 Mylan 1 vial AP FDA listed
Docetaxel 10 mg/mLNDC 50742-0431-08 Ingenus 1 vial Discontinued
Docetaxel 10 mg/mLNDC 50742-0463-16 Ingenus 1 vial Discontinued

Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.

Other drugs in the same treatment class

These are different medicines — not other versions of Docetaxel Injection — that fall in the same broad treatment class (antineoplastics,miscellaneous) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.

Identity & classification

GCN Seq No 067167
GCN 29662
HICL code 010280
Ingredient (HICL) Docetaxel
HIC1 code V
Therapeutic class — broad (HIC1) Neoplasms
HIC2 code V1
Therapeutic class — intermediate (HIC2) Antineoplastic Drugs
HIC3 code V1F
Therapeutic class — specific (HIC3) Antineoplastics,Miscellaneous
AHFS code 10:00.00.00
AHFS class Antineoplastic Agents
FDB label name DOCETAXEL 80 MG/8 ML VIAL
FDB brand name Docetaxel
Legend status F — Federal legend — prescription drug or device
Where does this data come from?
Identity codes come from First Databank (FDB) (HICL ingredient, HIC1–3 therapeutic-class hierarchy, GCN, AHFS class, legend status) and Medi-Span GPI, mapped from a representative affected NDC. Licensed reference data — for identification only.

Other oncology shortages

Docetaxel Injection shortage FAQs

Is Docetaxel Injection in shortage?
Yes — the FDA currently lists Docetaxel Injection in shortage (status: “To Be Discontinued”, first reported Feb 20, 2026). 2 of 2 products are affected. This is national, manufacturer-reported data, so your pharmacy may still have stock.
Which products are affected?
Docetaxel, Injection, 10 mg/1 mL (NDC 50742-431-08) (NDC 50742-0431-08); Docetaxel, Injection, 10 mg/1 mL (NDC 50742-463-16) (NDC 50742-0463-16). The full per-NDC list (availability, manufacturer and status) is in the table above — each NDC links to its own page.
When will Docetaxel Injection be available again?
The FDA does not publish a guaranteed restock date, and no estimated-recovery note is on file. Availability can change daily — confirm with your pharmacy.
Can I still get Docetaxel somewhere?
Other manufacturers (Hikma Pharmaceuticals USA Inc., Hospira, Inc., Sanofi-Aventis U.S. LLC and others) still market it and have not reported a shortage. See “Where else can I get Docetaxel Injection?” above — stock still varies by pharmacy.
What should I do if I take Docetaxel Injection?
Don’t stop or change it on your own. Ask your pharmacist whether they can order it from another manufacturer or a different strength/package size, and ask your prescriber about a long-term plan before your supply runs out.

Still have a question about the Docetaxel Injection shortage?

Ask a pharmacist about this shortage →
How to read the Supply-Risk rating
Low (1–2)Multiple manufacturers still supplying and most strengths or pack sizes sourceable.
Medium (3)Some constraint — fewer suppliers or a notable share of NDCs unavailable.
High (4–5)Down to a single source, most strengths or pack sizes unsourceable, or a long-running outage.
Where does this data come from?
Shortage records come from the FDA Drug Shortages Database API via openFDA (/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.
Data structure & sourcing designed and verified by Dr. Brian Staiger, PharmD.
← Back to all current drug shortages